Log In
Print
BCIQ
Print
Print this Print this
 

GeneFx Lung (formerly LungExpress Dx)

  Manage Alerts
Collapse Summary General Information
Company Med BioGene Inc.
Description15-gene expression-based assay that identifies patients with early stage non-small cell lung cancer (NSCLC) who are at higher and lower risks of mortality following surgical removal of their tumor
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentApproved
Standard IndicationCancer, Diagnostic
Indication DetailsClassify patients with early stage non-small cell lung cancer (NSCLC) into high- and low-risk prognostic groups
Regulatory Designation

U.S. - Undisclosed Review (Classify patients with early stage non-small cell lung cancer (NSCLC) into high- and low-risk prognostic groups)

Partner

Helomics Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today